Natalizumab for Achieving Relapse-Free, T1 Gadolinium-Enhancing-Lesion-Free, and T2 Lesion-Free Status in Japanese Multiple Sclerosis Patients: A Phase 2 Trial Subanalysis

[1]  V. Martinelli,et al.  Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies , 2016, Multiple sclerosis.

[2]  J. Kira,et al.  Long-term efficacy and safety of intramuscular interferon beta-1a: Randomized postmarketing trial of two dosing regimens in Japanese patients with relapsing-remitting multiple sclerosis. , 2016, Multiple sclerosis and related disorders.

[3]  H. Weiner,et al.  Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. , 2015, JAMA neurology.

[4]  L. Provinciali,et al.  Natalizumab Treatment in Multiple Sclerosis Patients: A Multicenter Experience in Clinical Practice in Italy , 2014, International journal of immunopathology and pharmacology.

[5]  B. Cree,et al.  Disease activity free status: a new end point for a new era in multiple sclerosis clinical research? , 2014, JAMA neurology.

[6]  L. Kappos,et al.  BG-12 (Dimethyl Fumarate) Treatment for Relapsing–Remitting Multiple Sclerosis (RRMS) Increases the Proportion of Patients Free of Measured Clinical and Neuroradiologic Disease Activity in the Phase 3 Studies (P07.106) , 2013 .

[7]  Jeffrey A. Cohen,et al.  Fingolimod Treatment Increases the Proportion of Patients Who Are Free from Disease Activity in Multiple Sclerosis Compared to IFN-b1a: Results from a Phase 3, Active-Controlled Study (TRANSFORMS) (PD5.006) , 2012 .

[8]  Y. Itoyama,et al.  A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis , 2012, Multiple sclerosis.

[9]  P. Vermersch,et al.  Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis , 2011, The Lancet Neurology.

[10]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[11]  Deborah M. Miller,et al.  Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight-year follow-up. , 2010, Archives of neurology.

[12]  C. Polman,et al.  Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study , 2009, The Lancet Neurology.

[13]  Ludwig Kappos,et al.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[14]  Christian Confavreux,et al.  Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[15]  S. Reingold,et al.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.

[16]  Y. Itoyama,et al.  Interferon beta-1b is effective in Japanese RRMS patients , 2005, Neurology.

[17]  C. Poser,et al.  Diagnostic criteria for multiple sclerosis , 2001, Clinical Neurology and Neurosurgery.

[18]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[19]  J. Kira,et al.  Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: A double-blind, randomized controlled trial and open-label pharmacokinetic study. , 2017, Multiple sclerosis and related disorders.